达格列净在血容量不足患者中的药学监护及文献分析

doi:10.5246/jcps.2022.09.061

中国药学(英文版) ›› 2022, Vol. 31 ›› Issue (9): 718-722.DOI: 10.5246/jcps.2022.09.061

达格列净在血容量不足患者中的药学监护及文献分析

袁叶, 于博, 杨珍珍, 董维冲, 杨秀岭^*()

河北医科大学第二医院, 河北石家庄 050000

收稿日期:2022-04-03 修回日期:2022-05-12 接受日期:2022-05-28 出版日期:2022-09-30 发布日期:2022-09-30
通讯作者: 杨秀岭
作者简介:
+ Tel.: +86-311-66003456, E-mail: yxl20031109@sina.com

Pharmacological monitoring and literature analysis of dagliflozin in patients with hypovolemia

Ye Yuan, Bo Yu, Zhenzhen Yang, Weichong Dong, Xiuling Yang^*()

The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China

Received:2022-04-03 Revised:2022-05-12 Accepted:2022-05-28 Online:2022-09-30 Published:2022-09-30
Contact: Xiuling Yang

摘要/Abstract

摘要：

本文探讨临床血容量不足的患者在使用达格列净降低血糖及改善心衰时的用药时机及临床药师在药学监护中的作用。临床药师参与两例血容量不足患者使用达格列净的用药方案, 建议血容量不足患者暂停使用该药物, 并查阅相关文献, 为临床医生提供理论依据, 发挥临床药师在药学服务中的作用。考虑患者出现血容量不足时, 临床药师能及时发现达格列净可降低血容量, 为患者用药提出合理建议及理论依据并被临床医生所采纳, 为患者制定个体化给药方案。本文提示临床药师在患者处于血容量不足时, 应重视达格列净的用药调整, 提高用药可导致不良影响的警惕性。

关键词: 达格列净, 血容量不足, 药学监护, 文献分析, 临床药师

Abstract:

: In the present study, we aimed to explore the timing of dosing with dapagliflozin (DAPA) in patients with hypovolemia and the role of the clinical pharmacist in pharmacological monitoring. The clinical pharmacist was involved in the dosing regimen of two patients with hypovolemia using DAPA and advising patients with insufficient blood volume to withhold the use of the drug. They reviewed the relevant literature to provide a theoretical basis for clinicians and the role of clinical pharmacists in pharmacy services. When considering patients with hypovolemia, the clinical pharmacist can promptly identify that DAPA can reduce blood volume and provide rational advice and rationale for the patient's medication that is adopted by the clinician, resulting in an individualized dosing regimen for the patient. Clinical pharmacists are advised to pay attention to the dosing adjustments of DAPA when patients are in hypovolemia and to be more alert to the adverse effects that can result from its use.

Key words: Dagliflozin, Hypovolemia, Pharmacological monitoring, Literature analysis, Clinical pharmacist

Supporting:

袁叶, 于博, 杨珍珍, 董维冲, 杨秀岭. 达格列净在血容量不足患者中的药学监护及文献分析[J]. 中国药学(英文版), 2022, 31(9): 718-722.

Ye Yuan, Bo Yu, Zhenzhen Yang, Weichong Dong, Xiuling Yang. Pharmacological monitoring and literature analysis of dagliflozin in patients with hypovolemia[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(9): 718-722.

参考文献 10

[1]	Wilding, J.; Bailey, C.; Rigney, U.; Blak, B.; Beekman, W.; Emmas, C. Glycated hemoglobin, body weight and blood pressure in type 2 diabetes patients initiating dapagliflozin treatment in primary care: a retrospective study. Diabetes Ther. 2016, 7, 695–711.
[2]	Wang, Y.; Sheng, S.X. Study on the protective mechanism of cardiovascular and renal function of Dagliflozin in type 2 diabetic patients. Chin. J. Prim. Med. Pharm. 2021, 28, 504–509.
[3]	Yang, Y. Effect of Dagliflozin on biochemical parameters, electrolytes and uric acid in type 2 diabetic patients. Chin. Foreign Med. Res. 2021, 19, 151–153.
[4]	Hallow, K.M.; Helmlinger, G.; Greasley, P.J.; McMurray, J.J.V.; Boulton, D.W. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes. Metab. 2018, 20, 479–487.
[5]	Liang, Z.S.; Xu, Z.M.; Ji, Q.W. Advances in evidence-based research on sodium-glucose cotransport protein 2 inhibitors in the treatment of heart failure and mechanisms. Chin. J. New Clin. Med. 2021, 14, 554–558.
[6]	McMurray, J.J.V.; Wheeler, D.C.; Stefánsson, B.V.; Jongs, N.; Postmus, D.; Correa-Rotter, R.; Chertow, G.M.; Hou, F.F.; Rossing, P.; Sjöström, C.D.; Solomon, S.D.; Toto, R.D.; Langkilde, A.M.; Heerspink, H.J.L.;. Effects of dapagliflozin in patients with kidney disease, with and without heart failure. JACC Heart Fail. 2021, 9, 807–820.
[7]	Liu, M.; Zhang, Y.M.; Feng, X.R.; Zheng, Q.; Wang, Y.C.; Liu, M.L. Short-term effects of dagliflozin on urine volume and blood and urine electrolytes in type 2 diabetic patients. Chin. J. Clin. Pharm. 2021, 37, 2569–2572.
[8]	Lambers Heerspink, H.J.; de Zeeuw, D.; Wie, L.; Leslie, B.; List, J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes. Metab. 2013, 15, 853–862.
[9]	Sha, S.; Polidori, D.; Heise, T.; Natarajan, J.; Farrell, K.; Wang, S.S.; Sica, D.; Rothenberg, P.; Plum-Mörschel, L. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 2014, 16, 1087–1095.
[10]	Dekkers, C.C.J.; Sjöström, C.D.; Greasley, P.J.; Cain, V.; Boulton, D.W.; Heerspink, H.J.L. Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes. Diabetes Obes. Metab. 2019, 21, 2667–2673.

达格列净在血容量不足患者中的药学监护及文献分析

Pharmacological monitoring and literature analysis of dagliflozin in patients with hypovolemia

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 10

相关文章 6

编辑推荐

Metrics

本文评价

[1]	常馨予, 韩丽娟, 刘洋, 范峥, 吴剑坤. 碳青霉烯类药物致血小板不良反应分析及相关文献回顾[J]. 中国药学(英文版), 2023, 32(10): 835-841.
[2]	武海艳, 王涛, 王倩, 唐琳. 新生儿无乳链球菌脑膜炎的抗感染治疗方案分析及停药指征探讨[J]. 中国药学(英文版), 2021, 30(8): 686-691.
[3]	朱愿超, 胡永芳, 杨莉萍, 胡欣. 临床药师干预对甲状腺手术围术期预防应用抗菌药物的影响[J]. 中国药学(英文版), 2015, 24(9): 617-624.
[4]	张金莲, 周佳, 陈霁晖, 陈婷, 刘艳, 田怀平, 张健. 临床药师对婴幼儿万古霉素血药浓度监测情况分析[J]. 中国药学(英文版), 2015, 24(4): 263-266.
[5]	包宁疆, 邵宏^*, 聂小燕, 吴永佩, 颜青, 李喜西, 杨巍, 王宁, 郑凯, 魏艳红, 史录文. 我国临床药师培训试点情况调查与分析[J]. , 2011, 20(4): 410-414.
[6]	李达, 邵宏^*. 药学监护中药物治疗问题的研究[J]. , 2009, 18(4): 354-357.